Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Health and Life Sciences at the Edge: Privacy Frameworks in Health and Life Sciences

The American Journal of Medicine noted that healthcare organizations, or HCOs, require a framework that preserves privacy and supports the kind of data collaboration that will make tomorrow’s scientific and clinical advances possible while still supporting improved patient outcomes and experiences. Establishing this framework is challenging. Can AI solutions meet those privacy requirements for healthcare…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The American Journal of Medicine noted that healthcare organizations, or HCOs, require a framework that preserves privacy and supports the kind of data collaboration that will make tomorrow’s scientific and clinical advances possible while still supporting improved patient outcomes and experiences. Establishing this framework is challenging. Can AI solutions meet those privacy requirements for healthcare and life science applications? This is the question host Hilary Kennedy posed to BeeKeeperAI’s CEO Michael Blum, MD and Intel’s Health and Life Sciences General Manager, Chris Gough.

“Even large health organizations do not have the diversity, quality, or amount of data required to create high-quality, generalizable AI,” said Blum. “The solution is a federated framework that allows each data steward to ensure the privacy of their data by keeping it in their protected cloud, while validating and training AI across all of those stewards.”

Gough agreed, saying, “If you can reduce the friction to accessing large, diverse, high-quality data sets – and use those data sets as part of the AI training step – then the algorithms that result will be more accurate for multiple populations.”

“Healthcare AI is projected to be a $46 billion dollar market. When you turn that into human impact, there’s a tremendous opportunity to improve the quality of care and reduce the cost of care,” said Blum. “But the challenge we see over-and-over again is that the algorithms don’t generalize across populations. Their accuracy and performance fall off dramatically. We have to get rapid access to much broader and much more diverse data sets.”

“We really have a supply and demand problem in healthcare,” Gough added. “AI will help the industry better target the scarce resources it has, allowing organizations to be less reactive and more proactive and predictive.”

To learn more about Michael Blum, MD, and Chris Gough:

Connect with them on LinkedIn

Visit https://www.beekeeperai.com/

Read the “Privacy-Preserving Data-Collaboration Methods that Accelerate Healthcare Innovation” white paper: https://www.intel.com/content/www/us/en/healthcare-it/resources/confidential-computing-whitepaper.html

Subscribe to this channel on Apple Podcasts, Spotify, or Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512